Better Health for All
-30
GSK aims to positively impact the health of 2.5 billion people by 2030 and reached at least 2 billion people by the end of 2024.
1
It supplied 672 million doses of products to lower-income countries in 2024 and donated 442 million albendazole tablets in 2024.
2
From 2019 to 2023, over two million children received at least one dose of the malaria vaccine (RTS,S/AS01).
3
The CARE-GSK partnership (2011-2021) reached 5.5 million people, leading to a 12.8% increase in contraceptive prevalence rate and reductions in maternal and infant mortality.
4
GSK was ranked second in the Access to Medicine Index (November 2024) and led the Antimicrobial Resistance Benchmark since 2018.
5
The company committed £1 billion over ten years to accelerate global health R&D in 2022, with 33% invested by the end of 2024.
6
It has over 30 R&D projects relevant to Antimicrobial Resistance, with 12 targeting critical pathogens.
7
GSK does not file or enforce patents for medicines in lower-income countries and supports generic versions of HIV products through voluntary licenses.
8
It offers HIV/AIDS medicines at not-for-profit prices in Least Developed Countries and sub-Saharan Africa, covering 80% of people living with HIV.
9
Prices for patented medicines in LDCs are capped at no more than 25% of developed country prices, with an average reduction of 45% for 11 brands since April 2009.
10
The price of its pneumococcal vaccine, Synflorix, is 10% of the cost in developed markets for Gavi-eligible countries.
11
GSK supplied over one billion vaccine doses to developing countries in 2010.
12
In 2024, GSK had two Class I and two Class II product recalls, received one critical finding from the MHRA, and incurred £7,900 in environmental fines.
13
It reduced Scope 1 and 2 carbon emissions by 36% from a 2020 baseline and overall water use by 28% from 2020.
14
GSK donated £2 million to aid agencies in 2024 for climate, health shocks, and armed conflict responses.
15
88% of managers undertook mental health training since 2019.
16
Since 2022, all phase III clinical trials have representation plans, with 88% meeting enrolment thresholds in 2024.
17
GSK's Niquitin team raised awareness of smoking cessation among ethnic populations.
18
Fair Money & Economic Opportunity
0
GSK is a biopharmaceutical company and does not offer lending or deposit services to consumers, nor does it provide consumer credit products.
1
Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcome, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its core business model as defined by the rubric. While GSK engages in various initiatives related to healthcare access, pricing strategies for medicines, and employee financial wellbeing, these do not fall under the scope of financial services for external consumers as required by the KPI definitions.
2
Fair Pay & Worker Respect
40
GSK states that all its workers are paid at or above the living wage in their relevant markets, and it was certified as a Living Wage employer in 2023.
1
The company's reportable injury and illness rate for 2024 was 0.24 per 100,000 hours worked, which translates to 0.48 per 200,000 hours, with zero fatalities for employees or contractors.
2
For 2024, the mean gender pay gap for all permanent UK-based employees was -1.03%, indicating women were paid more on average, and the median gender pay gap was -5.65%.
3
The mean bonus gap was 1.15%.
4
The employee engagement score for 2024 was 81%.
5
The voluntary employee turnover rate for 2024 was 5.3%.
6
In 2024, 32% of the global employee population was covered by collective bargaining arrangements.
7
In 2023, 15 major findings of labour rights non-compliance were found at 15 different suppliers, and seven incidents of labour rights non-compliance were found during site visits, with corrective action plans in progress or completed for most.
8
Fair Trade & Ethical Sourcing
-50
GSK re-assesses all existing suppliers once every three years on average.
1
In 2024, 12 major findings of labor rights non-compliance were reported at 12 different suppliers, and two incidents of labor rights non-compliance were found in China.
2
Six corrective action plans related to labor rights non-compliance were implemented, verified, and closed in 2023, with four further plans in progress.
3
In 2024, four corrective action plans were implemented, verified, and closed, with eight further plans in progress.
4
The company uses appropriate contract clauses for 528 high-risk third parties for labor rights.
5
GSK has identified 12 highest priority materials and developed sustainable sourcing standards for them.
6
The company increased year-on-year spend with suppliers owned by people in under-represented groups in the US, but a specific percentage of the procurement budget is not provided.
7
Honest & Fair Business
-30
GSK incurred regulatory fines totaling £8,100 in the past three years, with £200 in 2022 and £7,900 in 2024.
1
The company has a Controversy Exposure Score (CES) of 88/100.
2
GSK's 2019-2021 comparative results were restated to reflect the demerger of its Consumer Healthcare business.
3
The company encourages employees to 'Speak Up' about misconduct without fear of reprisal, offering multiple reporting channels including anonymous options where permissible, and 86% of employees believe they can and do speak up.
4
GSK provides anti-bribery and corruption (ABAC) training, with 100% of employees and 98% of complementary workers completing it.
5
The 2024 information underlying the Responsible Business Performance Rating has been subject to limited assurance by Deloitte.
6
GSK achieved a score of 78 in the S&P Global Corporate Sustainability Assessment.
7
Kind to Animals
0
No evidence available to assess GSK PLC LS-,3125 on Kind to Animals.
No War, No Weapons
-40
GSK, a biopharmaceutical company, has no reported revenue from arms or defense contracts, nor does it develop dual-use products for military applications.
1
In 2024, the company had gross revenues of £2.6 million from sales of medicines to Iran under a specific license, but ceased these exports in June 2024.
2
Additionally, it reported £7.3 million in gross revenues from sales to Lebanon in 2024.
3
In 2024, GSK invested approximately £27 million in health system strengthening, humanitarian support, and aid for armed conflict, which represents less than 0.5% of its 2025 total sales of £32.7 billion.
4
The Board-level Corporate Responsibility Committee oversees the company's approach to responsible business.
5
GSK conducts annual human rights due diligence in high-risk regions and re-assesses all existing suppliers every three years on average.
6
GSK's Human Rights Policy aligns with the UN Guiding Principles on Business and Human Rights, and it is a signatory to the UN Global Compact.
7
The company has global guidelines and policies on conflict minerals, and its suppliers did not indicate any conflict minerals from covered countries in 2024.
8
GSK's senior management is regularly briefed on due diligence efforts, and new or renewed supply agreements seek confirmation of conflict-free 3TG supplies.
9
GSK offers vaccines to civil society organizations serving refugees through the Humanitarian Mechanism since 2017.
10
The company has a global code of conduct setting out key ethical standards and principles, including zero tolerance of harassment.
11
GSK has Privacy Principles and a Privacy Policy requiring informed consent for personal information processing, with no indication of involvement in intelligence or surveillance contracts.
12
GSK submits an annual UN Global Compact Communication on Progress.
13
The company conducted a technical review of its products and surveyed suppliers for conflict minerals, updated via ongoing monitoring for 2024, but does not publish war-related supply chain risk audits.
14
GSK will contractually oblige existing suppliers sourcing conflict minerals in a manner that benefits armed groups to identify alternative sources, with failure resulting in termination of the supply agreement.
15
Planet-Friendly Business
-40
GSK's total estimated greenhouse gas emissions for 2023 were 9.63 million tonnes CO₂e.
1
The company's net-zero target for 2045 has been approved by the Science Based Target Initiative (SBTi) in line with their Corporate Net-Zero Standard, aiming to maintain global temperature increases below 1.5°C.
2
By 2024, GSK reached 90% imported renewable electricity, with a target to achieve 100% imported renewable electricity by 2025 and 100% renewable electricity (imported and generated) by 2030.
3
In 2024, 54% of materials were recovered via circular routes, and operational waste at GSK sites was reduced by 5% in 2024, a 25% reduction since 2020.
4
From 2024, all newly developed or acquired medicines will have Sustainable Design Plans applied.
5
GSK aims to secure high-quality carbon credits for 20% of residual emissions by 2030 and a maximum of 10% by 2045, investing in nature protection and restoration projects.
6
The company engages with its top 30 carbon-emitting suppliers, requiring them to disclose emissions and set 1.5°C-aligned carbon reduction targets; 22 of these suppliers have shared action plans.
7
66% of GSK sites are under biodiversity management plans, and 93% of paper packaging and core palm oil materials were certified as sustainable or from recycled sources in 2024.
8
GSK recorded environmental fines of £7,900 in 2024.
9
The company reports in line with the Task Force on Climate-related Financial Disclosures (TCFD) and provides climate risk and resilience disclosure in its annual report, including comprehensive scenario analysis for 1.5°C, 2°C, and 3°C+ pathways.
10
In 2024, 0.3 million m³ of water was used at high-water-risk sites.
11
GSK is working on an R&D program for a new inhaler propellant with the potential to reduce greenhouse gas emissions from inhalers by approximately 90%.
12
The company's investment in a peat and mangrove protection and restoration project in Indonesia includes training, sustainable economic activities, and a Healthy Village Program, addressing climate justice and adaptation.
13
Respect for Cultures & Communities
20
GSK has established 8 formal partnerships with indigenous or local community groups, including Worawa Aboriginal College, DENAT Group, Wayarang, Watershed Organisation Trust (WOTR), Women + Water Collaborative in India, 54 Reasons (focused on Doomadgee), mothers2mothers, and Last Mile Health.
1
The company reports no cultural appropriation incidents.
2
Grievance mechanisms are available to anyone inside or outside GSK, confidentially and anonymously, indicating coverage over 90% of operational sites.
3
GSK has invested in a community reforestation project in Ghana and a project in Indonesia to restore mangroves.
4
The company spent over $100,000 on Indigenous-owned businesses through Supply Nation.
5
GSK has taken actions to protect cultural sites, such as using Woi-wurrung language for meeting room names with support from the Wurundjeri Woi-wurrung Cultural Heritage Aboriginal Corporation.
6
The company translates its Annual Engagement and Culture Survey questions into 23 languages (excluding English).
7
Regarding cultural training, 32 employees completed the National Indigenous Training Employment Solutions (NITES) Cultural Appreciation eLearning program, 40 attended Worawa Aboriginal College Professional Learning Institute Cultural Appreciation Training, and 16 participated in a Cultural Walking Tour.
8
Safe & Smart Tech
0
GSK has an embedded cross-functional AI Governance Council (AIGC) to oversee AI strategy and ensure responsible adoption of AI/ML.
1
It introduced a new responsible AI Standard Operating Procedure defining requirements for all AI system development and procurement, and established a framework for integrating AI risk review and management within existing compliance boards.
2
The AIGC monitors regulatory updates to keep the Responsible AI Framework current.
3
GSK's cybersecurity awareness and training programs include phishing simulations, monthly awareness campaigns, and mandatory annual refreshers for all employees.
4
In 2024, 100% of employees and 99% of complementary workers completed this mandatory training.
5
AI review functions have been set up to conduct AI risk reviews and ensure compliance with internal and external standards.
6
GSK states it collects the minimum amount of personal information necessary for specific, explicit, and legitimate business purposes and retains it only as long as necessary.
7
However, it also states personal information is retained for 1-2 years for most data. GSK received one critical finding from the MHRA in 2024
8
and incurred a £1.8 billion charge for the Zantac settlement.
9
GSK has adopted Binding Corporate Rules (BCRs) for international transfers of personal information within its group, complying with EU and UK data protection laws.
10
The company's core team works to ensure privacy controls are built into all existing and new business initiatives and that accountability obligations are met in accordance with global data protection and privacy laws.
11
GSK takes its responsibility for data ethics and privacy seriously and exercises high standards of integrity in dealing with personal information.
12
Zero Waste & Sustainable Products
-40
GSK incurred multiple environmental and hazardous waste violations between 2014 and 2016, including a $317,550 hazardous waste violation
1
and an air pollution violation of $172,900 in 2014,
2
along with other environmental violations in 2015 ($24,200)
3
and 2016 ($5,259).
4
The company has set ambitious waste reduction targets, aiming for zero operational waste by 2030,
5
which includes a 20% reduction in operational waste from a 2020 baseline
6
and 100% operational waste circularity.
7
GSK also targets a 10% waste reduction from the supply chain by 2030
8
and a 25% environmental impact reduction for products and packaging by 2030.
9
GSK Consumer Healthcare aims for 100% of its product packaging to be recyclable or reusable by 2025.
10
GSK joined the Ellen MacArthur Network in 2020
11
and is a founding member of the Circularity in Primary Pharmaceutical Packaging Accelerator.
12
From 2024, all newly developed or acquired medicines will have Sustainable Design Plans applied.
13
Waste reduction initiatives include the "Complete the Cycle™ Recycle Program" for respiratory inhalers in 31 U.S. markets,
14
which diverts inhalers from landfills and recycles components.
15
Advil is reducing plastic in over 80 million bottles by 20%,
16
aiming to transition the portfolio by 2022,
17
which will reduce nearly 500,000 pounds of plastic.
18
GSK Consumer Healthcare is launching fully recyclable toothpaste tubes across its oral health brands
19
and plastic-free toothbrush packaging,
20
with Dr. Best packaging made from recycled cardboard.
21
Some paper packaging contains 50% or greater recycled content.
22
For suppliers, GSK assesses key suppliers for compliance with AMR Alliance and Wastewater API limits
23
and introduced the Sustainable Palm Index for palm oil and palm kernel oil derivatives suppliers.
24
A supplier, Albea, has committed to making 100% of their tubes recyclable by 2025.
25
Customer education is provided through a website and customer response center for the inhaler recycling program.
26
No facilities are reported to have zero waste certification.